Gilead Sciences is allowing six generic companies to sell lenacapavir at lower prices in 120 countries, aiming to expand H.I.V. treatment access, especially in sub-Saharan Africa.
While Gilead's generics deal enables broader access in lower-income regions, it excludes middle- and high-income countries, revealing a growing disparity in healthcare access among those populations.
Research indicates lenacapavir can be produced for as little as $40 per patient yearly, highlighting the substantial profit margin for Gilead despite significant differences in pricing for generics.
The deal is aimed at combatting the H.I.V. pandemic, yet Gilead's pricing strategy for middle-income nations raises concerns about equitable healthcare access for vulnerable populations.
Collection
[
|
...
]